The Trump administration is seeking to accelerate efforts to provide access to psychedelics for military veterans and others who may benefit from their therapeutic impact, but that push may be slowed when it comes to sourcing a particular substance to be used in studies, the head of the Department of Veterans Affairs (VA) says.
VA Secretary Doug Collins spoke about ongoing studies his department is conducting on the therapeutic benefits of psychedelics at a hearing before the Senate Veterans’ Affairs Committee on Thursday, saying that “if it helps a veteran, we’re going to look into it.”
He said that he appreciates President Donald Trump “stepping forward” on the issue by signing a psychedelics-focused executive order last month, noting that the administration’s work is a “combined effort” between VA and components of the Department of Health and Human Services (HHS).
After referencing VA’s recent expansion of trials on MDMA, which he said are proceeding “ahead of the schedule,” Collins noted that “our next probably big one” is going to be focused on ibogaine.
The secretary cautioned, however, that “it’s going to take a little time to get that, because we don’t have that.”
“That’s got to come through [the Food and
Read full article on Marijuana Moment
